Related references
Note: Only part of the references are listed.The evolution of natural killer cell receptors
Paola Carrillo-Bustamante et al.
IMMUNOGENETICS (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
Sumithira Vasu et al.
BLOOD (2016)
CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis
Marco Scarpa et al.
BMC CANCER (2016)
DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer
Krista P. Terracina et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Combining Epigenetic and Immunotherapy to Combat Cancer
Katherine B. Chiappinelli et al.
CANCER RESEARCH (2016)
The DNA methylation profile of activated human natural killer cells
John. K. Wiencke et al.
EPIGENETICS (2016)
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
Lorenzo Falchi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire
Jing Nie et al.
ONCOTARGET (2016)
Immune checkpoint blockade in hematologic malignancies
Philippe Armand
BLOOD (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
The Methylcytosine Dioxygenase Tet2 Promotes DNA Demethylation and Activation of Cytokine Gene Expression in T Cells
Kenji Ichiyama et al.
IMMUNITY (2015)
Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia
Claudio Fozza et al.
LEUKEMIA RESEARCH (2015)
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Christopher R. Cogle et al.
ONCOLOGIST (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Lei Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers
David A. Russler-Germain et al.
CANCER CELL (2014)
Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
Kate Stringaris et al.
HAEMATOLOGICA (2014)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues
M. Goswami et al.
LEUKEMIA (2014)
The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells
Yuuki Obata et al.
NATURE IMMUNOLOGY (2014)
5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
Thomas Stuebig et al.
MEDIATORS OF INFLAMMATION (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells
Xue Zhang et al.
EPIGENETICS & CHROMATIN (2014)
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
A. O. Gang et al.
BLOOD CANCER JOURNAL (2014)
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Omar Abdel-Wahab et al.
BLOOD (2013)
Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells
Yuxia Zhang et al.
BLOOD (2013)
Genomic impact of transient low-dose decitabine treatment on primary AML cells
Jeffery M. Klco et al.
BLOOD (2013)
Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide
Sandra Coral et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells
Alba Fernandez-Sanchez et al.
EPIGENETICS (2013)
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
Benedetta Costantini et al.
HAEMATOLOGICA (2013)
Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies
David Kosoff et al.
IMMUNOTHERAPY (2013)
Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions
Lisa M. Kopp et al.
MOLECULAR IMMUNOLOGY (2013)
A panoramic view of acute myeloid leukemia
Sai-Juan Chen et al.
NATURE GENETICS (2013)
Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
Li-Xin Wang et al.
PLOS ONE (2013)
Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL
Michael R. Verneris
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes
Hetty J. Bontkes et al.
LEUKEMIA RESEARCH (2012)
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
Wen-Chien Chou et al.
BLOOD (2011)
Evaluation of Current Cancer Immunotherapy Hemato-Oncology
Christopher S. Hourigan et al.
CANCER JOURNAL (2011)
Impact of the hypomethylating agent 5-azacytidine on dendritic cells function
Jihane Frikeche et al.
EXPERIMENTAL HEMATOLOGY (2011)
Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells
Ben Youngblood et al.
IMMUNITY (2011)
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
Benjamin J. Schmiedel et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Felicitas Thol et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2011)
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
Jaebok Choi et al.
BLOOD (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Maria E. Figueroa et al.
CANCER CELL (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko et al.
NATURE (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Current perspectives of natural killer cell education by MHC class I molecules
Petter Hoeglund et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Demethylating treatment suppresses natural killer cell cytolytic activity
Xiao-ning Gao et al.
MOLECULAR IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma
I Tirapu et al.
CANCER RESEARCH (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
DNA methylation maintains allele-specific KTR gene expression in human natural killer cells
HW Chan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells
S Santourlidis et al.
JOURNAL OF IMMUNOLOGY (2002)
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy
JK Christman
ONCOGENE (2002)
T-cell regulation by CD28 and CTLA-4
ML Alegre et al.
NATURE REVIEWS IMMUNOLOGY (2001)
Share Paper
